JP2001503620A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503620A5
JP2001503620A5 JP1998520446A JP52044698A JP2001503620A5 JP 2001503620 A5 JP2001503620 A5 JP 2001503620A5 JP 1998520446 A JP1998520446 A JP 1998520446A JP 52044698 A JP52044698 A JP 52044698A JP 2001503620 A5 JP2001503620 A5 JP 2001503620A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998520446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503620A (ja
Filing date
Publication date
Priority claimed from US08/740,215 external-priority patent/US5874566A/en
Application filed filed Critical
Publication of JP2001503620A publication Critical patent/JP2001503620A/ja
Publication of JP2001503620A5 publication Critical patent/JP2001503620A5/ja
Ceased legal-status Critical Current

Links

JP52044698A 1996-10-25 1997-08-29 インターロイキン遺伝子の発現を阻害するオリゴマー Ceased JP2001503620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/740,215 1996-10-25
US08/740,215 US5874566A (en) 1996-10-25 1996-10-25 Il-15 triplex oligonucleotides
PCT/US1997/015397 WO1998018812A1 (en) 1996-10-25 1997-08-29 Oligomers which inhibit the expression of interleukin genes

Publications (2)

Publication Number Publication Date
JP2001503620A JP2001503620A (ja) 2001-03-21
JP2001503620A5 true JP2001503620A5 (enExample) 2005-06-16

Family

ID=24975523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52044698A Ceased JP2001503620A (ja) 1996-10-25 1997-08-29 インターロイキン遺伝子の発現を阻害するオリゴマー

Country Status (7)

Country Link
US (1) US5874566A (enExample)
EP (1) EP0937099A4 (enExample)
JP (1) JP2001503620A (enExample)
KR (1) KR20000052806A (enExample)
AU (1) AU720110B2 (enExample)
CA (1) CA2269722A1 (enExample)
WO (1) WO1998018812A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) * 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
JP2002519439A (ja) * 1998-07-07 2002-07-02 久光製薬株式会社 Il−15に標的されたアンチセンスオリゴヌクレオチド
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
GB9910119D0 (en) * 1999-04-30 1999-06-30 Novartis Ag Organic compounds
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en) 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2003007685A2 (en) 2001-07-17 2003-01-30 University Of Florida Detecting and treating reproductive tract disorders
KR20040096554A (ko) 2002-02-06 2004-11-16 비코르 테크놀로지스 인코포레이티드 경색방지 분자
WO2003093452A2 (en) * 2002-02-26 2003-11-13 University Of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
CA2625349A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
EP2392646A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2664189C (en) 2006-09-21 2017-11-21 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
EP2288922B1 (en) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
CN106177930A (zh) 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
US9970002B2 (en) 2012-12-12 2018-05-15 Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
CN105960410B (zh) 2013-11-21 2020-12-04 硒瑞恩生物科技有限公司 硒衍生的核酸复合物的结构测定方法
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
JP2019524787A (ja) 2016-08-03 2019-09-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Tlr9標的治療薬
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
US20240083990A1 (en) 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2002514326A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2001504697A5 (enExample)
JP2001503295A5 (enExample)
JP2000501324A5 (enExample)
JP2000510176A5 (enExample)
JP2001518972A5 (enExample)
JP2000500026A5 (enExample)
JP2001501447A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2002515108A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2001503620A5 (enExample)
JP2001500541A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)